CD40 and neoplasm: In a different murine study, DC function, antigen-induced T cell priming and proliferation upon antigen presentation showed slight reduction at MEKi dosages sufficient for suppression of tumor growth only when co-administered with anti-CD40 agonistic Ab, supporting the notion that CD40 signaling could overcome the impaired priming (192).